Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CYTX
  • CUSIP: 23283K10
Key Metrics:
  • Previous Close: $1.71
  • 50 Day Moving Average: $1.67
  • 200 Day Moving Average: $1.79
  • 52-Week Range: $20,500,000.00 - $1.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.80
  • P/E Growth: 0.00
  • Market Cap: $35.06M
  • Outstanding Shares: 20,500,000
  • Beta: 2.69
Profitability:
  • Net Margins: -314.07%
  • Return on Equity: -172.63%
  • Return on Assets: -60.18%
Debt:
  • Debt-to-Equity Ratio: 0.89%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.57%
Additional Links:
Companies Related to Cytori Therapeutics:

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.25 (440.94% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017B. RileyReiterated RatingBuy$6.75View Rating Details
2/15/2017Maxim GroupBoost Price TargetBuy$6.00 -> $10.00View Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00View Rating Details
5/12/2015Ascendiant Capital MarketsInitiated CoverageBuy$18.75View Rating Details
4/7/2015LaidlawReiterated RatingBuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017($0.23)N/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.06)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.12)ViewN/AView Earnings Details
8/12/2014($0.11)($0.15)ViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($7.35)($7.35)($7.35)
Q3 20161($7.05)($7.05)($7.05)
Q4 20161($8.25)($8.25)($8.25)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 14.17%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline
News IconEPS Of Cytori Therapeutics Inc (NASDAQ:CYTX) At $-0.26 | Stock ... - Stock Observer (NASDAQ:CYTX)
www.thestockobserver.com - February 18 at 8:09 AM
4-traders.com logoCytori Therapeutics : Completes Acquisition of Azaya Therapeutics Assets, Initiates Nanomedicine Program (NASDAQ:CYTX)
www.4-traders.com - February 16 at 7:02 PM
seekingalpha.com logoCytori Therapeutics Inc (CYTX) (NASDAQ:CYTX)
seekingalpha.com - February 16 at 7:02 PM
istreetwire.com logoStocks To Watch: Stillwater Mining Company (SWC), HD Supply ... - iStreetWire (NASDAQ:CYTX)
istreetwire.com - February 16 at 2:00 PM
News IconNews Impact Score Of Cytori Therapeutics Inc (NASDAQ:CYTX) At 0 - Stock Observer (NASDAQ:CYTX)
www.thestockobserver.com - February 16 at 2:00 PM
News IconCytori Therapeutics (CYTX) Stock: Gaining On Price Target Increase - CNA Finance (press release) (NASDAQ:CYTX)
cnafinance.com - February 16 at 2:00 PM
streetinsider.com logoCytori Therapeutics, Inc. (CYTX) PT Raised to $10 at Maxim Group on Closure of the Azaya Deal - StreetInsider.com (NASDAQ:CYTX)
www.streetinsider.com - February 16 at 2:00 PM
finance.yahoo.com logoCytori Completes Acquisition of Azaya Therapeutics Assets, Initiates Nanomedicine Program (NASDAQ:CYTX)
finance.yahoo.com - February 16 at 2:00 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:CYTX)
biz.yahoo.com - February 16 at 2:00 PM
finance.yahoo.com logoCytori Provides Latest Corporate Update at the 2nd Annual Disruptive Growth & Healthcare Conference (NASDAQ:CYTX)
finance.yahoo.com - February 14 at 5:30 PM
News IconInvesting Focus: Indicators in View on Shares of Cytori Therapeutics Inc. (CYTX) - Rives Journal (NASDAQ:CYTX)
rivesjournal.com - February 13 at 10:22 PM
News IconTrading Scope: Checking the Levels for Cytori Therapeutics Inc. (CYTX) - Davidson Register (NASDAQ:CYTX)
davidsonregister.com - February 11 at 3:08 AM
investopedia.com logoCytori Wins Small Business Status, Stock Spikes (NASDAQ:CYTX)
www.investopedia.com - February 7 at 5:46 PM
investopedia.com logoCytori Wins Small Business Status, Stock Spikes (NASDAQ:CYTX)
www.investopedia.com - February 7 at 5:46 PM
nasdaq.com logoHealth Care Sector Update for 02/06/2017: CYTX,GALE,PETX - Nasdaq (NASDAQ:CYTX)
www.nasdaq.com - February 7 at 2:44 AM
gurufocus.com logoCytori Receives U.S. Small Business Designation - Substantially ... - GuruFocus.com (NASDAQ:CYTX)
www.gurufocus.com - February 7 at 2:44 AM
investingnews.com logoCytori Receives U.S. Small Business Designation (NASDAQ:CYTX)
investingnews.com - February 6 at 4:41 PM
us.rd.yahoo.com logoCytori Receives U.S. Small Business Designation - Substantially Reduces 2017 FDA Filing Fees (NASDAQ:CYTX)
us.rd.yahoo.com - February 6 at 4:41 PM
us.rd.yahoo.com logo9:02 am Cytori Therapeutics: FDA granted Small Business status to the co for FY 17; allows Cytori to receive 'significant' financial incentives, fee reductions, and fee waivers for selective FDA medical device regulatory filings (NASDAQ:CYTX)
us.rd.yahoo.com - February 6 at 4:41 PM
News IconNews Impact Score Of Cytori Therapeutics Inc (NASDAQ:CYTX) At 100 - Stock Observer (NASDAQ:CYTX)
www.thestockobserver.com - February 2 at 3:12 AM
News IconCheap Stock, But is it a Bargain: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Prospect Journal (NASDAQ:CYTX)
prospectjournal.com - January 31 at 3:35 AM
News IconStock Momentum in Focus on Shares of Cytori Therapeutics Inc. (CYTX) - Sherwood Daily (NASDAQ:CYTX)
sherwooddaily.com - January 28 at 4:13 AM
News IconCytori Therapeutics Inc (NASDAQ:CYTX) Quarterly EPS Projection At $-0.26 - Stock Observer (NASDAQ:CYTX)
www.thestockobserver.com - January 28 at 4:13 AM
News IconNarrowing in on Chart Levels for Cytori Therapeutics Inc. (CYTX) - Sherwood Daily (NASDAQ:CYTX)
sherwooddaily.com - January 26 at 5:52 PM
barrons.com logo[$$] Four Biotech Picks for Cures Law (NASDAQ:CYTX)
www.barrons.com - January 26 at 5:52 PM
News IconCytori Therapeutics Inc CYTX Financial and Strategic SWOT Analysis Review Prices from USD $125 (NASDAQ:CYTX)
www.bioportfolio.com - January 25 at 10:51 PM
News IconIgniting Curiosity on This Name, Investor Update on Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Prospect Journal (NASDAQ:CYTX)
prospectjournal.com - January 25 at 5:50 PM
News IconInvestors are Looking at Levels for Cytori Therapeutics Inc. (CYTX) - Sherwood Daily (NASDAQ:CYTX)
sherwooddaily.com - January 25 at 5:50 PM
News IconCytori Therapeutics Inc (CYTX) Valuation According To Analysts ... - UK Market News (NASDAQ:CYTX)
www.ukmarketnews.co.uk - January 24 at 10:20 PM
kcregister.com logoCytori Therapeutics (NASDAQ:CYTX) enter into an agreement to acquire certain assets from privately held Azaya ... - KC Register (NASDAQ:CYTX)
www.kcregister.com - January 23 at 9:58 PM
News IconPriming The Pump: Stock Volatility Spotted in Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Wall Street Beacon (NASDAQ:CYTX)
wsbeacon.com - January 23 at 9:58 PM
News IconFocus on RSI and CCI Levels: Cytori Therapeutics Inc. (CYTX) - Sherwood Daily (NASDAQ:CYTX)
sherwooddaily.com - January 20 at 10:50 PM
News IconPopping up on Watch-lists are Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Prospect Journal (NASDAQ:CYTX)
prospectjournal.com - January 20 at 10:50 PM
News IconAmplified Volatility Spotted in Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Wall Street Beacon (NASDAQ:CYTX)
wsbeacon.com - January 20 at 10:50 PM
streetinsider.com logoCytori Therapeutics (CYTX) to Acquire Assets from Privately Held Azaya Therapeutics - StreetInsider.com (NASDAQ:CYTX)
www.streetinsider.com - January 20 at 10:50 PM
investopedia.com logoCytori to Buy Cancer Drug Co. Azaya for $170M (CYTX) (NASDAQ:CYTX)
www.investopedia.com - January 20 at 5:50 PM
investopedia.com logoCytori To Buy Cancer Drug Group Azaya for $170M (NASDAQ:CYTX)
www.investopedia.com - January 20 at 5:50 PM
bizjournals.com logoSan Diego company to buy stalled San Antonio-based cancer drug developer (NASDAQ:CYTX)
www.bizjournals.com - January 19 at 10:59 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Netflix, Mallinckrodt, Rent-A-Center (NASDAQ:CYTX)
m.nasdaq.com - January 19 at 5:55 PM
streetinsider.com logoCytori Therapeutics (CYTX) to Acquire Assets from Privately Held Azaya Therapeutics (NASDAQ:CYTX)
www.streetinsider.com - January 19 at 5:55 PM
smarteranalyst.com logoMaxim Comments on Cytori Therapeutics Inc (CYTX) Following Azaya Acquisition (NASDAQ:CYTX)
www.smarteranalyst.com - January 19 at 5:55 PM
finance.yahoo.com logoCytori to Acquire Proprietary Nanoparticle Development Platform to Enhance Regenerative Medicine Leadership Position (NASDAQ:CYTX)
finance.yahoo.com - January 19 at 5:55 PM
finance.yahoo.com logoCytori to Acquire Proprietary Nanoparticle Development Platform to Enhance Regenerative Medicine Leadership Position (NASDAQ:CYTX)
finance.yahoo.com - January 19 at 5:55 PM
finance.yahoo.com logo7:02 am Cytori Therapeutics to acquire certain assets from Azaya Therapeutics; Cytori to issue $2 mln in common stock up front - shares halted (NASDAQ:CYTX)
finance.yahoo.com - January 19 at 5:55 PM
finance.yahoo.com logo7:02 am Cytori Therapeutics to acquire certain assets from Azaya Therapeutics; Cytori to issue $2 mln in common stock up front - shares halted (NASDAQ:CYTX)
finance.yahoo.com - January 19 at 5:55 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity (NASDAQ:CYTX)
biz.yahoo.com - January 19 at 5:55 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity (NASDAQ:CYTX)
biz.yahoo.com - January 19 at 5:55 PM
marketwatch.com logoCytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya Therapeutics (NASDAQ:CYTX)
www.marketwatch.com - January 19 at 5:55 PM
marketwatch.com logoCytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya Therapeutics (NASDAQ:CYTX)
www.marketwatch.com - January 19 at 5:55 PM
News IconHoning in on Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Prospect Journal (NASDAQ:CYTX)
prospectjournal.com - January 18 at 3:32 AM

Social

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics's stock reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

3 analysts have issued 1-year price targets for Cytori Therapeutics' stock. Their forecasts range from $6.75 to $11.00. On average, they expect Cytori Therapeutics' stock price to reach $9.25 in the next twelve months.

When will Cytori Therapeutics announce their earnings?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

What are analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (2/20/2017)

  • Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytori Therapeutics stock cost?

One share of Cytori Therapeutics stock can currently be purchased for approximately $1.71.

Cytori Therapeutics (NASDAQ:CYTX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Earnings History Chart

Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Dividend History Chart

Dividend Payments by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Last Updated on 2/27/2017 by MarketBeat.com Staff